The first domestically made alternative to a global blockbuster
Com a expiração da patente do Ozempic em março de 2026, o Brasil deu um passo significativo na democratização do acesso a tratamentos modernos para obesidade: a Anvisa aprovou o Ozivy, primeiro medicamento injetável à base de semaglutida produzido em solo nacional, desenvolvido pela farmacêutica EMS. O evento não é apenas regulatório — é um momento em que a soberania farmacêutica encontra uma demanda de saúde pública crescente, abrindo caminho para que mais brasileiros possam acessar uma classe de medicamentos que redefiniu o tratamento do sobrepeso no mundo.
- A aprovação do Ozivy pela Anvisa encerra um processo de três anos iniciado pela EMS em 2023, sinalizando que o mercado brasileiro de emagrecedores injetáveis está prestes a se transformar.
- A expiração da patente do Ozempic em março de 2026 funcionou como um gatilho: onde havia monopólio, agora há corrida — cinco versões sintéticas e uma biológica de semaglutida ainda aguardam análise na agência.
- A tensão central é de acesso: medicamentos importados e de marca única mantiveram preços elevados e criaram escassez; um concorrente doméstico muda essa equação.
- O Ozivy chega não como exceção, mas como primeiro de uma série — o pipeline da Anvisa indica que a competição no segmento das 'canetas emagrecedoras' está apenas começando.
- Para o sistema de saúde brasileiro, a trajetória aponta para preços menores e maior disponibilidade, mas o ritmo e os valores finais ao consumidor ainda estão por ser definidos.
A Anvisa aprovou o Ozivy, medicamento injetável à base de semaglutida fabricado pela EMS, tornando-o o primeiro produto doméstico dessa classe a receber aval regulatório no Brasil. A decisão marca uma virada: até agora, o acesso a esse tipo de tratamento dependia de versões importadas, sobretudo do Ozempic, que dominou o mercado global e gerou escassez em diversos países.
O contexto é determinante. Em março de 2026, a patente do Ozempic expirou, desbloqueando legalmente o caminho para que outras empresas desenvolvessem suas próprias versões. A EMS antecipou esse movimento e protocolou o pedido de registro junto à Anvisa ainda em 2023. Após três anos de avaliação técnica — que verificou eficácia, segurança e qualidade de fabricação —, a aprovação veio em maio de 2026.
O Ozivy não chega sozinho. Outros seis produtos à base de semaglutida, entre sintéticos e biológicos, estão em análise na Anvisa, e mais pedidos aguardam na fila. O mercado brasileiro das chamadas 'canetas emagrecedoras' está prestes a se tornar muito mais competitivo. Para pacientes e para o sistema de saúde, isso significa uma perspectiva concreta de preços menores e acesso mais amplo — não como promessa futura, mas como processo já em curso.
Brazil's health regulator has cleared the way for a domestically manufactured weight-loss injection to reach the market. The Agência Nacional de Vigilância Sanitária, or Anvisa, approved Ozivy, a semaglutide-based medication produced by the pharmaceutical company EMS. The approval marks a significant shift: for the first time, Brazilians will have access to a locally made version of the drug class that has reshaped conversations about weight management globally.
The timing matters. Ozempic, the original branded semaglutide injection that captured worldwide attention and sparked shortages, saw its patent protection expire in March of this year. That expiration opened the door for competitors to develop their own versions. EMS, one of Brazil's major pharmaceutical manufacturers, seized the opportunity. The company filed its registration request with Anvisa back in 2023, beginning a three-year journey through the agency's standard approval process.
The path from application to approval followed established protocol. Anvisa's technical team evaluated whether Ozivy met the baseline requirements: did it work as claimed, was it safe for patients, and did the manufacturing process maintain consistent quality? The company provided the evidence, the agency reviewed it, and in May 2026, the approval came through. EMS had followed the chronological queue and priority system that Anvisa uses to manage applications for GLP-1 medications—the formal name for this class of weight-loss drugs that have become colloquially known as "canetas emagrecedoras," or slimming pens.
But Ozivy is not arriving into a vacuum. Five other synthetic semaglutide formulations and one biologically derived version are currently moving through Anvisa's review process. Several more applications are waiting in line. What this suggests is that the Brazilian pharmaceutical landscape is about to become considerably more crowded in this therapeutic category. The expiration of Ozempic's patent has essentially unlocked a wave of domestic competition.
For patients and the Brazilian health system, the implications are substantial. A domestically produced medication typically costs less than an imported one, both because manufacturing happens locally and because competition drives prices down. Ozivy's approval signals that affordable access to semaglutide-based treatment is no longer a distant prospect—it is beginning now. The question that follows is not whether more options will arrive, but how quickly, and at what price points.
Notable Quotes
The application followed chronological order and priority procedures for GLP-1 medications— Anvisa
The Hearth Conversation Another angle on the story
Why did it take three years from application to approval if the drug is essentially a copy of something already proven safe?
Because Anvisa doesn't take shortcuts. Even though semaglutide itself is well-established, EMS had to prove that their specific formulation, their manufacturing process, their quality controls—all of it—met the standard. It's not about reinventing the wheel; it's about verifying that this particular wheel won't fall off.
And the patent expiration in March—was that the trigger for EMS to file, or were they already working on this?
The application came in 2023, so EMS was already moving before the patent died. But the expiration certainly changed the calculus. Once Ozempic's protection ended, the market became genuinely open. Suddenly there was no legal barrier to competition.
Six more versions in the pipeline. Does that mean prices are about to collapse?
Not collapse, but yes, downward pressure. When you have multiple manufacturers competing for the same patient population, margins compress. That's the whole point of patent expiration—it's supposed to democratize access.
Who benefits most from this? The wealthy who were already buying Ozempic, or people who couldn't afford it before?
The latter. The wealthy already had access. This is about the middle and lower-income population who were priced out. A domestic generic or biosimilar at a fraction of the imported cost changes who can actually afford treatment.
What happens to the companies still waiting in line for approval?
They're watching closely. Ozivy's approval proves the pathway works. It also means they know what Anvisa expects. But they're also racing against each other—first to market often means first to capture market share, even in a crowded field.